Latest news with #Alkermes
Yahoo
02-06-2025
- Business
- Yahoo
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on and will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at Alkermes Contact: Jamie ConstantineInvestor Relations+1 781 873 2402 View original content to download multimedia: SOURCE Alkermes plc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on and will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at Alkermes Contact: Jamie ConstantineInvestor Relations+1 781 873 2402 View original content to download multimedia: SOURCE Alkermes plc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Alcohol Use Disorder (AUD) Market Trends and Forecasts (2025-2030) by Drug Class, Treatment Type, End User, Distribution Channel, Formulation, Region and Country
Featuring Profiles of Key Players Alkermes, H. Lundbeck, Teva Pharmaceutical Industries, Viatris, Sandoz International and More Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Alcohol Use Disorder Market by Drug Class, Treatment Type, End User, Distribution Channel, Formulation - Global Forecast to 2030" report has been added to Alcohol Use Disorder Market grew from USD 1.28 billion in 2024 to USD 1.37 billion in 2025. It is expected to continue growing at a CAGR of 6.60%, reaching USD 1.88 billion by landscape of AUD treatment is undergoing transformative shifts that redefine conventional paradigms and unlock new avenues for patient engagement. Digital health solutions, exemplified by teletherapeutic platforms and mobile applications, are enhancing adherence and extending the reach of behavioral interventions. Concurrently, regulatory bodies are recalibrating approval pathways to accommodate novel modalities, from sustained-release injectables to adaptive combination therapies. This convergence of technological innovation and regulatory agility accelerates the translation of research breakthroughs into clinical trends further inform strategic pivots, as rising incidence in younger cohorts compels the design of more personalized, stigma-sensitive outreach programs. Pharmaceutical developers are responding by enhancing patient support services and leveraging real-world evidence to optimize dosing regimens. Meanwhile, payers are reassessing reimbursement frameworks to reward value-based outcomes over volume-driven metrics. Collectively, these shifts signal a more integrated, patient-centric future for AUD management, where therapy personalization and outcome measurement coalesce to improve both clinical efficacy and economic the Ramifications of 2025 United States Tariffs on AUD TherapiesThe imposition of United States tariffs in 2025 has reverberated throughout the global supply chain for AUD therapies, prompting a reassessment of sourcing strategies and cost structures. Raw material levies on key active pharmaceutical ingredients have elevated production expenses, particularly for excipients integral to effervescent and sustained-release formulations. Manufacturers reliant on international chemical suppliers have encountered upward price pressure, resulting in margin compression and, in some cases, temporary repricing at the point of mitigate these effects, several drug producers have expedited domestic procurement agreements and invested in localized manufacturing capabilities. While these measures enhance supply chain resilience, they require significant capital outlays and extended lead times. Payers and providers have also felt the ripple effects, with negotiated contract terms evolving to accommodate incremental cost burdens. Amid these market dynamics, strategic collaboration between pharmaceutical companies and contract manufacturers has emerged as a critical lever to safeguard continuity of supply and protect patient access. The collective response underscores the delicate interplay between trade policy and therapeutic availability in the AUD Dynamics Shaping the AUD MarketRegional dynamics exert a powerful influence on the trajectory of AUD treatments. In the Americas, robust healthcare infrastructure and substantial public funding underpin expansive adoption of both pharmacotherapies and integrated behavioral programs. The United States remains the epicenter of innovation, supported by a comprehensive network of academic research centers and a growing emphasis on telemedicine reimbursement. Latin American markets are witnessing gradual uptake, driven by rising incidence rates and policy initiatives aimed at expanding rural healthcare Europe, Middle East and Africa, market maturity varies widely. Western European nations boast well-established reimbursement frameworks and stringent regulatory processes, fostering incremental innovation in drug delivery and patient support models. In contrast, emerging markets in the Middle East and parts of Africa contend with limited infrastructure and variable regulatory oversight, creating both challenges and opportunities for suppliers willing to invest in capacity-building partnerships and localized Asia-Pacific region presents a dual narrative of rapid urbanization and shifting cultural attitudes toward alcohol use. Markets such as China, India and Australia are allocating increased resources toward AUD screening and treatment integration within primary care settings. Government initiatives aimed at destigmatizing behavioral therapy are gaining momentum, while private sector players explore digital therapeutics to overcome geographic barriers. Collectively, these regional insights underscore the necessity of geographically tailored strategies that align with local regulatory environments, payer structures and patient engagement Landscape and Key Industry PlayersThe competitive landscape of AUD therapeutics features established pharmaceuticals alongside emerging biotechnology innovators. Leading companies have fortified their market positions through strategic product life-cycle management, launching reformulated versions and extended-release alternatives to prolong patent exclusivity. Some firms have executed targeted acquisitions to integrate niche behavioral health capabilities or expand geographic reach, while others have forged co-development agreements to share R&D costs and accelerate pipeline entrants are disrupting traditional paradigms by advancing novel delivery systems and repurposing existing compounds for adjunctive use. Several players are exploring advanced drug-device combinations to optimize dosing adherence, while digital health start-ups collaborate with pharmaceutical sponsors on teletherapy platforms that integrate electronic patient-reported outcomes. Formulary negotiations and patient assistance programs have become critical battlegrounds, with manufacturers deploying real-world evidence and health economics data to secure favorable reimbursement this milieu, companies that demonstrate agility in regulatory navigation, supply chain optimization and stakeholder engagement are poised to gain competitive advantage. The continual interplay between legacy portfolio optimization and next-generation product introductions shapes the contours of market leadership and defines the success metrics for future Imperatives for Industry LeadershipIndustry leaders must adopt proactive strategies that anticipate evolving market demands and regulatory shifts. First, deepening investments in digital health integration will bridge gaps between pharmacotherapy and behavioral interventions, enhancing patient retention and improving long-term outcomes. Deploying advanced analytics to personalize treatment pathways can also heighten efficacy and reduce dropout rates. Second, strengthening partnerships with contract manufacturing organizations can mitigate supply chain disruptions triggered by external trade policies, ensuring consistent product availability across diverse forging alliances with payers and provider networks to design value-based reimbursement models will be essential for demonstrating cost-effectiveness and driving formulary placement. Collaborative real-world evidence initiatives can substantiate clinical and economic benefits, paving the way for risk-sharing agreements. Finally, expanding into underserved and emerging markets requires tailored go-to-market approaches that address local infrastructure constraints and cultural attitudes toward behavioral health. By proactively implementing these imperatives, industry stakeholders can navigate uncertainty and secure sustained growth in the accelerating AUD Segmentation & CoverageThis research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations: Drug Class Acamprosate Effervescent Tablet Oral Tablet Disulfiram Oral Tablet Naltrexone Injectable Oral Tablet Treatment Type Behavioral Therapy Cognitive Behavioral Therapy Family Therapy Motivational Enhancement Therapy Combined Therapy CBT With Pharmacotherapy MET With Pharmacotherapy Pharmacotherapy Injectable Drugs Oral Drugs End User Home Healthcare Home Visits Telehealth Hospitals Private Hospitals Public Hospitals Rehabilitation Centers Inpatient Outpatient Specialty Clinics Alcohol Rehabilitation Clinics Psychiatric Clinics Distribution Channel Hospital Pharmacies Private Hospital Pharmacies Public Hospital Pharmacies Online Pharmacies E-Commerce Websites Mobile Apps Retail Pharmacies Chain Pharmacies Independent Pharmacies Specialty Pharmacies AUD Specialty Pharmacies General Specialty Pharmacies Formulation Dispersible Tablet Effervescent Tablet Injectable Intramuscular Intravenous Subcutaneous Oral Tablet Immediate Release Sustained Release This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions: Americas United States California Texas New York Florida Illinois Pennsylvania Ohio Canada Mexico Brazil Argentina Europe, Middle East & Africa United Kingdom Germany France Russia Italy Spain United Arab Emirates Saudi Arabia South Africa Denmark Netherlands Qatar Finland Sweden Nigeria Egypt Turkey Israel Norway Poland Switzerland Asia-Pacific China India Japan Australia South Korea Indonesia Thailand Philippines Malaysia Singapore Vietnam Taiwan This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies: Alkermes plc H. Lundbeck A/S Teva Pharmaceutical Industries Ltd. Viatris Inc. Sandoz International GmbH Dr. Reddy's Laboratories Ltd. Sun Pharmaceutical Industries Ltd. Aurobindo Pharma Ltd. Lupin Limited Cipla Limited Key Attributes Report Attribute Details No. of Pages 192 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $1.37 Billion Forecasted Market Value (USD) by 2030 $1.88 Billion Compound Annual Growth Rate 6.6% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Boston Globe
19-05-2025
- Business
- Boston Globe
It's not just Harvard: Ballard Partners, lobbying firm with Trump ties, lines up Mass. clients
In D.C., it's another story entirely: Politico reported that Ballard raked in $14 million in lobbying fees in the first quarter, or roughly triple what it generated the same time a year ago, making it one of the busiest lobbying firms in Washington this year. A search of the federal government's lobbying database shows more than 90 new clients hired Ballard in the first four months of the year. (A spokesman for Ballard declined to comment.) Advertisement Among them were Teradyne, a North Reading manufacturer in the semiconductor industry, and Alkermes, a biopharma company that's technically based in Ireland but has its biggest corporate-and-lab facility in Waltham. Neither returned requests for comment about Ballard's hiring. In its filings, Alkermes said it tapped Ballard to 'provide guidance and advice regarding mental health, public health and regulatory reform,' while Teradyne cited 'export control regulation interpretation.' Advertisement Sublime Systems, a Somerville startup, depends heavily on federal funding for a factory it's building in Holyoke to make low-carbon cement. Spokeswoman Erin Glabets declined to comment about Ballard's hiring, although the stated purpose in Sublime's federal filing is 'advocacy and guidance related to energy grants.' The company recently secured a federal tax credit worth nearly $50 million, along with up to $87 million that the US Department of Energy awarded Sublime last year for the project. Glabets said those awards remain unchanged, and the company is moving ahead with engineering and permitting, with a goal of opening the Holyoke plant in 2027. The Mass. hospital association also offered a statement about why it hired Ballard that didn't mention Trump: 'Ballard has a strong history of representing safety net hospitals, and our engagement comes during a critical moment when our safety net infrastructure is faltering and decisions around the future of Medicaid funding are being made. In addition to our national consultants at [law firm] Alston & Bird, they are an important component of MHA's mission to protect healthcare organizations, patients, and caregivers here in Massachusetts.' Advertisement Jon Chesto can be reached at
Business Insider
02-05-2025
- Business
- Business Insider
Mizuho Securities Reaffirms Their Buy Rating on Alkermes (ALKS)
Mizuho Securities analyst Uy Ear maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of $40.00. The company's shares closed today at $30.58. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Ear is an analyst with an average return of -3.5% and a 34.48% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and Evolus. In addition to Mizuho Securities, Alkermes also received a Buy from TD Cowen's Joseph Thome in a report issued today. However, on April 28, UBS maintained a Hold rating on Alkermes (NASDAQ: ALKS).
